Current understanding of diagnosis, treatment and predictors of papillary thyroid microcarcinoma progression
https://doi.org/10.14341/ket12813
Abstract
Papillary Microcarcinoma of the Thyroid Gland (PMTC) is the most common type of malignant thyroid neoplasm, characterized by its small size and generally favorable prognosis. The increased detection rate of PMTC is associated with advancements in high-precision diagnostic methods such as ultrasound and fine-needle aspiration biopsy. Diagnostic approaches include the use of the EU-TIRADS and Bethesda systems for risk assessment, as well as the analysis of molecular markers, such as BRAF gene mutations and promising studies on the role of microRNAs in predicting tumor progression.
Optimal management of patients with PMTC requires an individualized therapeutic approach due to differences in disease progression. This article analyzes current diagnostic and treatment methods for PMTC, including the use of molecular-genetic markers, minimally invasive technologies, and active surveillance strategies, with an emphasis on a personalized approach to prognosis and therapy.
About the Authors
A. V. Dzodzaeva
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Aria V. Dzodzaeva, MD
11 Dm. Ulyanova street, 117292, Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
E. V. Bondarenko
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Ekaterina V. Bondarenko, MD, PhD
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
M. A. Terekhova
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Maria A. Terekhova, MD
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
A. V. Vanushko
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Aleksandra V. Vanushko, MD
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
V. E. Vanushko
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Vladimir E. Vanushko, MD, PhD
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
E. A. Troshina
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Ekaterina A. Troshina, MD, PhD, Professor
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
References
1. Bi J, Zhang H. A meta-analysis of total thyroidectomy and lobectomy outcomes in papillary thyroid microcarcinoma. Medicine (Baltimore). 2023;102(50):e36647. doi: https://doi.org/10.1097/MD.0000000000036647
2. Wang Y, Li L, Wang Y-XJ, et al. Ultrasound Findings of Papillary Thyroid Microcarcinoma: A Review of 113 Consecutive Cases with Histopathologic Correlation. Ultrasound Med Biol. 2012;38(10):1681-1688. doi: https://doi.org/10.1016/j.ultrasmedbio.2012.05.019
3. Kilfoy BA, Zheng T, Holford TR, et al. International patterns and trends in thyroid cancer incidence, 1973–2002. Cancer Causes Control. 2009;20(5):525-531. doi: https://doi.org/10.1007/s10552-008-9260-4
4. State of oncological care for the Russian population in 2023 / Ed. A. D. Kaprina, V. V. Starinskogo, A.O. Shakhzadovoi. M.: P. A. Herzen MSIOI – filial of NMRC of radiology Ministry of Public Health of the Russian Federation, 2024. – 262p. (In Russ)
5. Magra V., et al. Frequency of Thyroid Microcarcinoma in Patients Who Underwent Total Thyroidectomy with Benign Indication — A 5-Year Retrospective Review. Medicina. 2024;60(3):468. doi: https://doi.org/10.3390/MEDICINA60030468
6. Arican CD, Ozturk T, Sager MS, et al. Incidental Papillary Microcarcinoma and Papillary Thyroid Carcinoma in Multinodular Goiter. Tuccari G, ed. Anal Cell Pathol. 2023;2023(1). doi: https://doi.org/10.1155/2023/2768344
7. El Omri M., et al. Aggressive papillary microcarcinoma: clinical manifestations and prognostic factors. Endocrine Abstracts. 2024;99. doi: https://doi.org/10.1530/ENDOABS.99.EP486
8. Yang F, Wang J, Rao Y, Feng Y, Meng L, Fang J. Predictive factors and risk analysis of recurrent laryngeal nerve invasion in papillary thyroid carcinoma ≤ 1 cm. Arch Endocrinol Metab. January 2023. doi: https://doi.org/10.20945/2359-3997000000537
9. Uppal N, Collins R, James B. Thyroid nodules: Global, economic, and personal burdens. Front Endocrinol (Lausanne). 2023;14. doi: https://doi.org/10.3389/fendo.2023.1113977
10. Alexander EK, Cibas ES. Diagnosis of thyroid nodules. Lancet Diabetes Endocrinol. 2022;10(7):533-539. doi: https://doi.org/10.1016/S2213-8587(22)00101-2
11. Horvath E, Majlis S, Rossi R, et al. An Ultrasonogram Reporting System for Thyroid Nodules Stratifying Cancer Risk for Clinical Management. J Clin Endocrinol Metab. 2009;94(5):1748-1751. doi: https://doi.org/10.1210/jc.2008-1724
12. Russ G, Bonnema SJ, Erdogan MF, Durante C, Ngu R, Leenhardt L. European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS. Eur Thyroid J. 2017;6(5):225-237. doi: https://doi.org/10.1159/000478927
13. Trimboli P, Ngu R, Royer B, et al. A multicentre validation study for the EU‐TIRADS using histological diagnosis as a gold standard. Clin Endocrinol (Oxf). 2019;91(2):340-347. doi: https://doi.org/10.1111/cen.13997
14. Friguglietti CUM, Dutenhefner SE, Brandão LG, Kulcsar MAV. Classification of papillary thyroid microcarcinoma according to size and fine-needle aspiration cytology: Behavior and therapeutic implications. Head Neck. 2011. doi: https://doi.org/10.1002/hed.21517
15. Burgess JR, Tucker P. Incidence Trends for Papillary Thyroid Carcinoma and Their Correlation with Thyroid Surgery and Thyroid Fine-Needle Aspirate Cytology. Thyroid. 2006;16(1):47-53. doi: https://doi.org/10.1089/thy.2006.16.47
16. Abrosimov AY, Abdulkhabirova FM, Shifman BM. Limitation of possibilities of cytological diagnosis of papillary thyroid cancer at the pre-surgery stage. Arkh Patol. 2020. doi: https://doi.org/10.17116/patol20208203124
17. Sakorafas GH, Giotakis J, Stafyla V. Papillary thyroid microcarcinoma: A surgical perspective. Cancer Treat Rev. 2005;31(6):423-438. doi: https://doi.org/10.1016/j.ctrv.2005.04.009
18. Hsiao V, Light TJ, Adil AA, et al. Complication Rates of Total Thyroidectomy vs Hemithyroidectomy for Treatment of Papillary Thyroid Microcarcinoma. JAMA Otolaryngol Neck Surg. 2022;148(6):531. doi: https://doi.org/10.1001/jamaoto.2022.0621
19. So YK, Kim MW, Son Y-I. Multifocality and Bilaterality of Papillary Thyroid Microcarcinoma. Clin Exp Otorhinolaryngol. 2015;8(2):174. doi: https://doi.org/10.3342/ceo.2015.8.2.174
20. Nagaoka R, Ebina A, Toda K, et al. Multifocality and Progression of Papillary Thyroid Microcarcinoma During Active Surveillance. World J Surg. 2021;45(9):2769-2776. doi: https://doi.org/10.1007/s00268-021-06185-2
21. Zhang M, Tufano RP, Russell JO, et al. Ultrasound-Guided Radiofrequency Ablation Versus Surgery for Low-Risk Papillary Thyroid Microcarcinoma: Results of Over 5 Years’ Follow-Up. Thyroid. 2020;30(3):408-417. doi: https://doi.org/10.1089/thy.2019.0147
22. Ji L, Wu Q, Gu J, et al. Ultrasound-guided percutaneous laser ablation for papillary thyroid microcarcinoma: a retrospective analysis of 37 patients. Cancer Imaging. 2019;19(1):16. doi: https://doi.org/10.1186/s40644-019-0204-x
23. Yue W-W, Qi L, Wang D-D, et al. US-guided Microwave Ablation of Low-Risk Papillary Thyroid Microcarcinoma: LongerTerm Results of a Prospective Study. J Clin Endocrinol Metab. 2020;105(6):1791-1800. doi: https://doi.org/10.1210/clinem/dgaa128
24. Ito Y, Miyauchi A, Fujishima M, Yamamoto M, Sasaki T. Active surveillance for adult low-risk papillary thyroid microcarcinoma — a review focused on the 30-year experience of Kuma Hospital—. Endocr J. 2024;71(1):EJ23-0395. doi: https://doi.org/10.1507/endocrj.EJ23-0395
25. Sugitani I. Active surveillance of low-risk papillary thyroid microcarcinoma. Best Pract Res Clin Endocrinol Metab. 2023;37(1):101630. doi: https://doi.org/10.1016/j.beem.2022.101630
26. Oda H, Miyauchi A, Ito Y, et al. Comparison of the costs of active surveillance and immediate surgery in the management of low-risk papillary microcarcinoma of the thyroid. Endocr J. 2017;64(1):59-64. doi: https://doi.org/10.1507/endocrj.EJ16-0381
27. Lai M, Zhang MM, Qin QQ, An Y, Li YT, Yuan WZ. Cost-effectiveness of active surveillance versus early surgery for thyroid micropapillary carcinoma based on diagnostic and treatment norms in China. Front Endocrinol (Lausanne). 2023;14. doi: https://doi.org/10.3389/fendo.2023.1166433
28. Moon JH, Ryu CH, Cho SW, et al. Effect of Initial Treatment Choice on 2-year Quality of Life in Patients with Low-risk Papillary Thyroid Microcarcinoma. J Clin Endocrinol Metab. 2021;106(3):724-735. doi: https://doi.org/10.1210/clinem/dgaa889
29. Kong SH, Ryu J, Kim MJ, et al. Longitudinal Assessment of Quality of Life According to Treatment Options in Low-Risk Papillary Thyroid Microcarcinoma Patients: Active Surveillance or Immediate Surgery (Interim Analysis of MAeSTro). Thyroid. 2019. doi: https://doi.org/10.1089/thy.2018.0624
30. Nickel B, Brito JP, Moynihan R, Barratt A, Jordan S, McCaffery K. Patients’ experiences of diagnosis and management of papillary thyroid microcarcinoma: a qualitative study. BMC Cancer. 2018;18(1):242. doi: https://doi.org/10.1186/s12885-018-4152-9
31. Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient Age Is Significantly Related to the Progression of Papillary Microcarcinoma of the Thyroid Under Observation. Thyroid. 2014;24(1):27-34. doi: https://doi.org/10.1089/thy.2013.0367
32. Ito Y, Miyauchi A, Fujishima M, et al. Thyroid-Stimulating Hormone, Age, and Tumor Size are Risk Factors for Progression During Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma in Adults. World J Surg. 2023. doi: https://doi.org/10.1007/s00268-022-06770-z
33. Kayhan Y, Azizova L, Yilmaz M, et al. Predictive factors affecting prognosis in papillary thyroid microcarcinomas. Endocr Abstr. May 2023. doi: https://doi.org/10.1530/endoabs.90.P512
34. Aksenova TN, Bondarenko EV, Ioutsi VA, Abdulkhabirova FM, Vanushko VE, et al. Potential protein markers for differential diagnosis of thyroid neoplasms. Clinical and experimental thyroidology. 2024;20(1):56-67. (In Russ.) doi: https://doi.org/10.14341/KET12786
35. Kim MJ, Kim JK, Kim GJ, et al. TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea. Cancers (Basel). 2022;14(19):4928. doi: https://doi.org/10.3390/cancers14194928
36. Lee J, Ha EJ, Roh J, Kim HK. Presence of TERT ± BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma. Surg (United States). 2021. doi: https://doi.org/10.1016/j.surg.2021.03.056
37. Ciampi R, Nikiforov YE. RET/PTC Rearrangements and BRAF Mutations in Thyroid Tumorigenesis. Endocrinology. 2007;148(3):936-941. doi: https://doi.org/10.1210/en.2006-0921
38. Lukyanov SA, Titov SE, Kozorezova ES, Demenkov PS, Veryaskina YA, et al. Prediction of the Aggressive Clinical Course of Papillary Thyroid Carcinoma Based on Fine Needle Aspiration Biopsy Molecular Testing. Int J Mol Sci. 2024 Jun 28;25(13):7090. doi: https://doi.org/10.3390/ijms25137090
39. Ruiz-Pozo VA, Cadena-Ullauri S, Guevara-Ramírez P, Paz-Cruz E, Tamayo-Trujillo R, Zambrano AK. Differential microRNA expression for diagnosis and prognosis of papillary thyroid cancer. Front Med. 2023;10. doi: https://doi.org/10.3389/fmed.2023.1139362
40. Qiu Z, Li H, Wang J, Sun C. miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma. Oncol Rep. 2017;38(5):2735-2740. doi: https://doi.org/10.3892/or.2017.5994
41. Shen R, Liyanarachchi S, Li W, et al. MicroRNA Signature in Thyroid Fine Needle Aspiration Cytology Applied to “Atypia of Undetermined Significance” Cases. Thyroid. 2012;22(1):9-16. doi: https://doi.org/10.1089/thy.2011.0081
42. Vriens MR, Weng J, Suh I, et al. MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer. 2012;118(13):3426-3432. doi: https://doi.org/10.1002/cncr.26587
Review
For citations:
Dzodzaeva A.V., Bondarenko E.V., Terekhova M.A., Vanushko A.V., Vanushko V.E., Troshina E.A. Current understanding of diagnosis, treatment and predictors of papillary thyroid microcarcinoma progression. Clinical and experimental thyroidology. 2024;20(3):14-20. (In Russ.) https://doi.org/10.14341/ket12813
Views:
607
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
